Serotonin News and Research

Latest Serotonin News and Research

Elorac acquires world-wide rights to Cidoxepin

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, is pleased to announce that it has acquired world-wide rights to the active agent Cidoxepin from Gideon Pharmaceuticals. Cidoxepin is the cis-isomer of the widely prescribed tricyclic compound doxepin.

19 Oct 2010

Researchers discover gene that contributes to depression

Yale University researchers have found a gene that seems to be a key contributor to the onset of depression and is a promising target for a new class of antidepressants, they report Oct. 17 in the journal Nature Medicine.

18 Oct 2010

Study: Characteristics of children with OCD could help predict personalized medicine approach

New research from the Bradley Hasbro Children's Research Center may help clinicians better predict how a child with obsessive compulsive disorder (OCD) will respond to some of the most commonly used treatment approaches. The findings, published in the October issue of the Journal of the American Academy of Child and Adolescent Psychiatry, could help guide important clinical decisions about the best intervention for children with this often debilitating anxiety disorder.

15 Oct 2010

Study finds TMS is an effective treatment solution for major depression

Transcranial magnetic stimulation (TMS), the treatment delivers a series of electrical pulses to the part of the brain associated with depression and other mood disorders. The pulses generate an electric current in the brain that stimulates neurons to increase the release of more mood-enhancing chemicals like serotonin, dopamine and norepinephrine.

15 Oct 2010

Smart for Life(R) to add Lepticore(R) to product line

Smart for Life(R), the trailblazing company featuring weight management products will begin adding Lepticore(R) to its product line this month.

12 Oct 2010

Phase 3 study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors

The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.

11 Oct 2010

Abbott to withdraw Meridia medicine from the U.S. market

Abbott will voluntarily withdraw Meridia (sibutramine) from the U.S. market at the request of the U.S. Food and Drug Administration (FDA).

11 Oct 2010

Fisher Wallace Laboratories launches easy-to-use medical device for depression treatment

Fisher Wallace Laboratories today announced the launch of a bold YouTube video campaign that challenges the pharmaceutical drug industry and introduces the company's easy-to-use medical device prescribed for the self-treatment of depression: the Fisher Wallace Cranial Stimulator.

6 Oct 2010

Study may lend insight about hallucination mechanism in schizophrenia

Scripps Research Institute scientists have shown for the first time that the neurotransmitter serotonin uses a specialized signaling pathway to mediate biological functions that are distinct from the signaling pathways used by hallucinogenic substances. The new findings could have a profound effect on the development of new therapies for a number of disorders, including schizophrenia and depression.

6 Oct 2010

Supplemental brief dynamic therapy does not benefit patients with obsessive-compulsive disorder: Study

This study demonstrates that supplemental brief dynamic therapy in the treatment of patients with obsessive compulsive-disorder with concurrent major depressive disorder (who are receiving effective medication) has no significant clinical effect on both obsessive and depressive symptoms.

5 Oct 2010

Researchers reveal ways to halt Rett Syndrome

In a study published today in the Journal, Proceedings of the National Academy of Sciences, an international team of researchers based in the U.S. and UK revealed that they were able to halt the potentially lethal, breath holding episodes associated with the neurological disease Rett syndrome.

5 Oct 2010

Maternal serotonin deficiency linked to development of ADHD in children

Children whose mothers are genetically predisposed to have impaired production of serotonin appear more likely to develop attention-deficit hyperactivity disorder (ADHD) later in life, according to a report in the October issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

5 Oct 2010

Neuro-Biotech introduces biomarker for progressive clinical investigation on Alzheimer's Disease

Neuro-Biotech Corporation introduces a Neuro-biomarker which is linked to a series of Neuro-Bio tests. This will permit to understand the science behind them and how they each will contribute to a progressive clinical investigation involving the input and output of the brain.

5 Oct 2010

J&JPRD receives FDA Complete Response Letter for tapentadol ER tablets NDA

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for tapentadol extended release tablets.

4 Oct 2010

IRSF awards $1.5M in research grants for Rett syndrome treatment

The International Rett Syndrome Foundation (IRSF) announced today that it will award an additional $1.5M in research grants, bringing the 2010 total to $2.15 million for innovative basic and translational research that moves treatments for Rett syndrome a step closer to the clinic.

4 Oct 2010

New SymPath kit measures DBH activity of Sympathetic Nervous System

Biotech Corporation in acquiring licenses to commercialize 12 Neuro-biomarkers has first focused on SymPath(R) and is now ready to give you the opportunity to shed some light about this Neuro-biomarker of the Sympathetic Nervous System (SNS). Here is a peak into the research behind the Neuro-blood testing that will be available to all patients through their health system.

4 Oct 2010

Increase in sales of new antidepressants not linked to decline in suicide rate

Many researchers have studied the relationship between the increase in sales of new antidepressants in recent decades and a simultaneous decline in the suicide rate. In a study based on figures from the Nordic countries, researchers at the Norwegian Institute of Public Health found no evidence that increased sales of the new medicines could be linked to a lower suicide rate. The researchers also did not find any relationship between reduced sales of the older and more toxic antidepressants and a reduction in suicide rates.

30 Sep 2010

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic low back pain have been published online by Expert Opinion on Pharmacotherapy. In addition, this study compared oxycodone controlled-release (CR) to placebo as an active control.

28 Sep 2010

Researchers explain how nerve cells transmit electrical signals

Billions of brain cells are communicating at any given moment. Like an organic supercomputer they keep everything going, from breathing to solving riddles, and "programming errors" can lead to serious conditions such as schizophrenia, Parkinson's disease and attention-deficit hyperactivity disorder.

22 Sep 2010

Arena, Eisai provide update on lorcaserin NDA

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 9 to 5 that the available data do not adequately demonstrate that the potential benefits of lorcaserin outweigh the potential risks, when used long-term in a population of overweight and obese individuals to allow marketing approval.

17 Sep 2010